The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in
most prostate tumors and at increased levels in metastatic castration-resistant prostate …

Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a
new wave of promising immunotherapies for the treatment of cancer. Their mechanism of …

Cancer is the leading cause of death worldwide. Cancer immunotherapy involves
reinvigorating the patient's own immune system to fight against cancer. While novel …

Simple Summary Cancer treatments have significantly changed with the introduction of
immunotherapy. Recently, the development of new agents that harness the redirection of T …

Highlights•Blinatumomab was the first TCE to be FDA-approved for treating cancer.•TCE
design evolved to improve safety, efficacy and manufacturability.•Single-chain variable …

We present the preclinical pharmacology of BNT142, a lipid nanoparticle (LNP)–formulated
RNA (RNA-LNP) encoding a T cell–engaging bispecific antibody that monovalently binds …

Regulated induced proximity targeting chimeras (RIPTACs), a new class of
heterobifunctional molecules, show promise in specifically targeting and eliminating cancer …

Bispecific antibodies exhibit proven clinical benefit, and many bispecifics are currently in
clinical development for oncology. Cytokine release syndrome (CRS) is a common clinical …